Mirum Pharmaceuticals/$MIRM
1D1W1MYTD1Y5YMAX
Capital at risk
About Mirum Pharmaceuticals
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
- Ticker
- $MIRM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 433
- Headquarters
- Foster City, United States
- Website
- www.mirumpharma.com
MIRM Metrics
BasicAdvanced
$6.6B
-
-$15.34
0.51
-
Price and volume
Market cap
$6.6B
Beta
0.51
52-week high
$130.00
52-week low
$63.23
Average daily volume
624K
Financial strength
Current ratio
2.856
Quick ratio
2.62
Long term debt to equity
-7,297.486
Total debt to equity
-7,320.562
Interest coverage (TTM)
-7.16%
Profitability
EBITDA (TTM)
-70.283
Gross margin (TTM)
81.72%
Net profit margin (TTM)
-139.18%
Operating margin (TTM)
-15.57%
Effective tax rate (TTM)
-0.31%
Revenue per employee (TTM)
$1,430,000
Management effectiveness
Return on assets (TTM)
-6.79%
Return on equity (TTM)
-702.97%
Valuation
Price to revenue (TTM)
9.159
Price to book
-626.92
Price to tangible book (TTM)
-25.34
Price to free cash flow (TTM)
-21.465
Free cash flow yield (TTM)
-4.66%
Free cash flow per share (TTM)
-4.701
Growth
Revenue change (TTM)
44.02%
Earnings per share change (TTM)
1,173.67%
3-year revenue growth (CAGR)
74.77%
3-year earnings per share growth (CAGR)
47.27%
What the Analysts think about MIRM
Analyst ratings (Buy, Hold, Sell) for Mirum Pharmaceuticals stock.
Analyst projections of the future price of Mirum Pharmaceuticals stock.
Bulls say / Bears say
Net product sales rose to $176.24 million in Q2 2026, prompting Mirum to lift its full-year 2026 net product sales guidance to $680 million–$700 million (Reuters)
Volixibat met the primary endpoint in the Phase 2b VISTAS study in PSC, reducing severe itch scores by 1.64 points placebo-adjusted, underscoring robust pipeline momentum (Reuters)
Completed the January 2026 acquisition of Bluejay Therapeutics for up to $820 million, adding brelovitug in late-stage development for HDV and diversifying its rare-disease portfolio (Reuters)
Q2 operating expenses of $218.78 million outpaced net product sales of $176.24 million, reflecting continued high cash burn and pressure on profitability (Reuters)
Concentration risk: a large share of revenue remains tied to a limited number of rare-disease products, exposing earnings to volatility if any key product falters (Reuters)
Shares plunged 23.9% after-hours on news that the FDA recommended an additional Phase 3 trial for volixibat in PSC, delaying the NDA submission to H1 2027 and underscoring regulatory execution risk (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
MIRM Financial Performance
Revenues and expenses
MIRM Earnings Performance
Company profitability
Upcoming events
No upcoming events
MIRM News
AllArticlesVideos
Funds containing MIRM
AllUSDGBPEUR
Fund name | Fund size | $MIRM weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.48% |
iShares Nasdaq US Biotechnology£BTEK | £867M | 0.48% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.15% |
iShares MSCI World Small Cap$WSML | $9B | 0.05% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.